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Abstract  35 
Background: Autologous Chondrocyte Implantation (ACI) has a failure rate of approximately 20% but 36 
we are yet to fully understand why. Biomarkers are needed that can pre-operatively predict which 37 
patients are likely to fail, so that alternative or individualised therapies can be offered. We previously 38 
used a label-free (LF) quantitation with dynamic range compression proteomic approach to assess 39 
the synovial fluid (SF) of ACI responders and non-responders. However, we were only able to identify 40 
a few differentially abundant proteins at baseline. Here, we build upon these previous findings by 41 
assessing higher abundance proteins within these SFs, providing a more global proteome analysis 42 
from which we can understand more of the biology underlying ACI success or failure. 43 
Methods: Isobaric tagging for relative and absolute quantitation (iTRAQ) proteomics was used to 44 
assess SFs from ACI responders (mean Lysholm improvement of 33; n=14) and non-responders 45 
(mean Lysholm decrease of 14; n=13) at the two stages of surgery (cartilage harvest and chondrocyte 46 
implantation). Differentially abundant proteins in iTRAQ and combined iTRAQ and LF datasets were 47 
investigated using pathway and network analyses.  48 
Results: iTRAQ proteomics has confirmed our previous finding that there is a marked proteome shift 49 
in response to cartilage harvest (70 and 54 proteins demonstrating ≥2.0 fold change and p<0.05 50 
between Stages I and II in responders and non-responders, respectively).  Further, it has highlighted 51 
28 proteins that were differentially abundant between responders and non-responders to ACI, that 52 
were not found in the LF study, 16 of which were altered at baseline. The differential expression of 53 
two proteins (complement C1S subcomponent and matrix metalloproteinase 3 (MMP3)) was 54 
confirmed biochemically. Combination of the iTRAQ and LF proteomic datasets has generated in-55 
depth SF proteome information that has been used to generate interactome networks representing 56 
ACI success or failure. Functional pathways that are dysregulated in ACI non-responders have been 57 
identified, including acute phase response signalling.  58 
Conclusions: Several candidate biomarkers for baseline prediction of ACI outcome have been 59 
identified. A holistic overview of the SF proteome in responders and non-responders to ACI has been 60 
profiled providing a better understanding of the biological pathways underlying clinical outcome, 61 
particularly the differential response to cartilage harvest in non-responders.  62 
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Background 92 
Identification of putative biomarkers that can be used to predict patient outcome prior to treatment for 93 
cartilage injury has been highlighted as a key initiative for the prevention of osteoarthritis (OA) by the 94 
Osteoarthritis Research Society International (OARSI) (1). Further, the recent National Institute for 95 
Health and Care Excellence (NICE) recommendation for use of the cell therapy Autologous 96 
Chondrocyte Implantation (ACI), in the UK National Health Service (NHS) has increased the need to 97 
identify accurate prognostic biomarkers for this application (2).  98 
We recently published the first study (3), to our knowledge, that has used a proteomic approach with 99 
the aim of identifying candidate biomarkers to predict the success of ACI, a cellular therapy for the 100 
treatment of traumatic cartilage injury (4,5). This therapy is a two-stage procedure; during the initial 101 
surgery (Stage I) healthy cartilage is harvested from a minor load-bearing region of the joint, then 102 
chondrocytes are isolated and culture expanded for three to four weeks prior to a second surgery in 103 
which the chondrocytes are implanted into the cartilage defect (Stage II) (5,6).  Approximately 500 104 
patients have been treated with ACI in our centre and despite an 81% success rate (7), we are yet to 105 
fully understand why some individuals fail to respond well. We have identified a biomarker, 106 
aggrecanase-1, that when its activity is un-detectable pre-operatively, can be used together with 107 
known demographic and injury-associated risk factors to help predict ACI success (8,9). However, we 108 
are yet to identify a biomarker (or panel of biomarkers) that can be used to accurately predict ACI 109 
failure. The identification of such a biomarker(s) for ACI and other cartilage repair strategies would 110 
allow for the better stratification of patients’ prior to joint surgery and may provide candidates for 111 
therapies to improve ACI success. 112 
Proteomic analyses remain one of the most widely used methods to identify novel biomarker 113 
candidates and have previously been utilised to identify biomarkers of OA progression (as 114 
summarised by Hsueh et al. in 2014 (10)). The synovial fluid (SF) provides an attractive biological 115 
fluid for biomarker identification, as it bathes the injured joint and therefore contains proteins that 116 
might reflect the whole joint environment. Proteomic profiling of the SF, however, is technically difficult 117 
due to the broad dynamic range of proteins present within it (7,8). Several un-biased, global 118 
proteomic studies for the identification of biomarkers within the SF have been completed. 119 
Nevertheless, the number of protein ‘hits’ has been somewhat limited, as authors have tended to 120 
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either profile SFs with no pre-treatment to account for the wide range of proteins (11–16) or have 121 
depleted high abundance proteins (17–22) meaning that the altered quantities of these proteins 122 
cannot be considered. 123 
Isobaric tags for absolute and relative quantitation (iTRAQ) is reported as the most accurate labelling 124 
method for quantifying comparative abundance of proteins (23). When compared to label free (LF) 125 
quantitation proteomics, iTRAQ quantitation has traditionally been considered as a more accurate 126 
technique (24); however as mass spectrometers improve, these techniques are becoming more 127 
comparable and LF quantitation is becoming increasingly popular (25). Unlike LF quantitation 128 
proteomics, iTRAQ utilises isobaric tags to label the primary amines at the peptide level, prior to 129 
pooling the samples to enable simultaneous identification and quantitation of the proteins.  4plex and 130 
8plex labels are available enabling quantitation of up to 8 conditions in a single analysis, thus 131 
minimising the number of mass spectrometry runs which can be cost effective and time efficient. 132 
However, when compared to LF quantitation, in which any number of samples can be analysed and 133 
compared, iTRAQ labelling limits the number of samples that can be compared, meaning biological 134 
replicate samples are often pooled together into relevant biological conditions. iTRAQ proteomics is a 135 
commonly used tool for the identification of biomarkers in a plethora of diseases. This proteomic 136 
approach has been used to profile the SF proteome (20,26), successfully identifying differentially 137 
abundant protein biomarker candidates for several diseases/conditions.  138 
Our previous study highlighted the potential of using protein equalisation to study low abundance 139 
proteins in human SF, but this identified few differentially abundant proteins in baseline SF, when 140 
comparing individuals who did or did not do well following cartilage repair therapy (1). This study, 141 
therefore, aimed to increase the number of protein biomarker candidates that could be identified for 142 
the pre-operative prediction of clinical outcome following ACI and to allow for the assessment of high 143 
abundance proteins which may also strengthen our understanding of the biological processes 144 
underlying treatment success.  145 
 146 
 147 
 148 
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Methods 149 
Synovial fluid collection and storage 150 
SF was collected, as described previously (3,8,27), from the knee joints of patients, with informed 151 
consent and following local research ethical approval. Immediately prior to both ACI surgeries, Stage I 152 
(cartilage harvest) and Stage II (chondrocyte implantation), 20 mL of saline was injected into the joint 153 
and 20 rounds of leg flexion and extension carried out to allow aspiration of as much SF as possible 154 
(3,27). SF was then centrifuged at 6,000 g for 15 minutes at 4°C and split into aliquots for long-term 155 
storage in liquid nitrogen. The dilution factor of the SF samples was calculated by comparing urea 156 
content in SF to matched blood plasma using a QuantiChrom
TM
 Urea Assay kit (BioAssay Systems, 157 
Hayward, USA) according to manufacturer’s instructions, as described previously (3,8,28) and SF 158 
samples with a dilution factor greater than 10 were excluded from the study.    159 
Clinical responders to ACI were defined as individuals who demonstrated an increase of at least 10 160 
points in the Lysholm score at 12 months post-treatment compared to their baseline score, as has 161 
been used previously (29–31). The Lysholm score is a validated (32), patient-self assessment score, 162 
encompassing knee pain and joint function that ranges from 0-100, with 100 representing ‘perfect’ 163 
knee function (32,33). Thirteen patients were considered as non-responders to ACI, demonstrating a 164 
mean decrease in Lysholm score of 14 points (range -4 - -46) and 14 SF donors were considered 165 
responders with a mean improvement of 33 points (range 17-54).                                                        166 
Sample preparation and analysis using iTRAQ proteomics (iTRAQ nLC-MS/MS)  167 
Total protein was quantified using a PierceTM 660nm protein assay (Thermo Scientific, Hemel 168 
Hempstead, UK) (34) and a total of 200 µg of SF protein was pooled equally from the donors in each 169 
of the following experimental groups: Stage I, responders (n=8); Stage I, non-responders (n=7); Stage 170 
II responders (n=12) and Stage II, non-responders (n=12). The pooled samples were then 171 
precipitated in six volumes of ice-cold acetone overnight at -20˚C. The precipitates were pelleted by 172 
centrifugation at 13,000 g for 10 mins at 4˚C before being re-suspended in 200 µl triethylammonium 173 
bicarbonate (TEAB) buffer. Eighty five micrograms of protein for each experimental sample was then 174 
subjected to reduction, alkylation (as instructed in the iTRAQ labelling kit (Applied Biosystems, 175 
Bleiswijk, Netherlands)). Sequencing grade modified trypsin (Promega) (10 µg per 85 µg of protein)  176 
7 
 
 177 
Table 1: Demographic data for patient samples from Stage I or Stage II were analysed, those who responded well clinically (responders) or who did not 178 
respond well (non-responders) to autologous chondrocyte implantation (ACI) are indicated in separate groups. None of the demographic parameters, other 179 
than a difference in Lysholm score, showed differences between responders (R) and non-responders (NR) in individuals whose SFs from Stage I (SI) or 180 
Stage II (SII) were compared, nor were there differences between individuals who were either responders or non-responders when comparing Stage I and 181 
Stage II samples (p≥0.05; Mann-Whitney U).  Data are median (range). Abbreviations: BMI, body mass index; LFC, lateral femoral condyle; LTP, lateral tibial 182 
plateau; MFC, medial femoral condyle.183 
 Stage I Stage II Mann-Whitney U 
(p-value) 
(A)R v NR- SI; (B) R 
v NR- SI 
Mann-Whitney U 
(p-value) 
(A)SI v SII-R; (B) SI v 
SII- NR  
Responders (n=8) Non-responders (n=7) Responders (n=12) Non-responders (n=12) 
Difference in Lysholm Score 
27 (17-38) -8 (-4- -17) 34 (17-54) -11 (-4 - -46) 
(A) 0.0003; (B) 
<0.0001 
(A) 0.21; (B) 0.55 
BMI (kg/m
2
) 29 (23-31) 27 (24-31) 27 (23-48) 29 (22-36) 
(A) 0.94; (B) 0.54 (A) 0.73; (B) 0.68 
Age (years) 32 (17-49) 40 (25-50) 40 (17-90) 43 (25-52) 
(A) 0.28; (B) 0.92 (A) 0.17; (B) 0.58 
Male/Female (No. of participants) 8/0 7/0 11/1 10/2 
(A) >0.99; (B) >0.99 (A) >0.99; (B) 0.51 
Smoker (No. of participants) 1 2 1 3 
(A) 0.54; (B) 0.59 (A) >0.99; (B) >0.99 
Dilution Factor of SF 5 (3-9) 4 (2-7) 4 (1-9) 3 (2-5) 
(A) 0.48; (B) 0.25 (A) 0.53; (B) 0.50 
Total defect area (cm
2
) 14 (0.4-24) 6 (0.6-12) 6 (1-20) 5 (0.6-12) 
(A) 0.74; (B) 0.35 (A) 0.45; (B) 0.28 
Patella defect (No. of participants) 1 1 4 2 
(A) >0.99; (B) 0.64 (A) 0.60; (B) >0.99 
LFC defect (No. of participants) 2 0 0 0 
(A) 0.47; (B) >0.99 (A) 0.15; (B) >0.99  
LTP defect (No. of participants) 1 0 0 0 
(A) >0.99; (B) >0.99 (A) 0.15; (B) >0.99 
MFC defect (No. of participants) 2 2 1 6 
(A) >0.99; (B) 0.07 (A) 0.54; (B) 0.63 
Trochlea defect (No. of participants) 0 3 2 1 
(A) 0.20; (B) >0.99 (A) 0.49; (B) 0.12 
Multiple defects (No. of participants) 1 0 1 1 
(A) >0.99; (B) >0.99 (A) >0.99; (B) >0.99 
Unknown defect location (No. of 
participants) 1 1 4 2 
(A) >0.99; (B) 0.64 (A) 0.60; (B) >0.99 
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was then added to the samples for overnight digestion at 37˚C. Tryptic digests were labelled with the 184 
iTRAQ tags, according to manufacturer’s instructions: 114- Stage II, responders; 115- Stage II, non-185 
responders; 116- Stage I, responders; 117- Stage I, non-responders, before being pooled to one 186 
microcentrifuge tube prior to being dried down in a vacuum centrifuge.  187 
iTRAQ- labelled peptides were resuspended in 0.6 mL of loading Buffer Ascx (10 mM monopotassium 188 
phosphate (KH2PO4), 20% acetonitrile (MeCN), pH 3.0), followed by sonication. The pH was adjusted 189 
to 3.0 with 0.5 M orthophosphoric acid (H3PO4). The peptides were separated by strong cation 190 
exchange chromatography as described previously (35). A total of 14 SCX fractions were analysed by 191 
nanoLC ESI MSMS using a TripleTOF 5600 tandem mass spectrometer (ABSciex, Foster City, CA) 192 
as described previously (36)  193 
The raw mass spectrometry data file was subsequently analysed using ProteinPilot 4.5 software with 194 
the Paragon™ and ProGroup™ algorithms (ABSciex) against the human sequences in the Swiss-Prot 195 
database (downloaded Dec 2012). Searches were performed using the pre-set iTRAQ settings in 196 
ProteinPilot. Trypsin was selected as the cleavage enzyme and MMTS for the modification of 197 
cysteines with a “Thorough ID” search effort. ProteinPilot’s Bias correction assumes that most 198 
proteins do not change in expression. Finally, detected proteins were reported with a Protein 199 
Threshold [Unused ProtScore (confidence)] >0.05 and used in the quantitative analysis if they were 200 
identified with two or more unique peptides with 95% confidence or above. P-values and false 201 
discovery rates for the iTRAQ ratios were calculated by the ProteinPilot software. Proteins with iTRAQ 202 
ratios with p-values ≤0.05 and with differential abundances of ≥±2.0 fold change (FC) were used in 203 
further analysis.  204 
Verification of iTRAQ nLC-MS/MS results using Enzyme Linked Immunosorbant Assay (ELISA) 205 
Two proteins of biological relevance were measured by ELISA in the non-pooled samples to verify the 206 
mass -spectrometry findings. Firstly, Complement C1S subcomponent (C1s) was selected, as this 207 
protein demonstrated differential abundance between responders and non-responders to ACI within 208 
the baseline SF (prior to Stage I surgery) and, therefore, could have potential as a biomarker of 209 
outcome prediction. C1s was assessed using a human ELISA (Cusabio, USA). Samples were first 210 
assayed using a 1 in 100 dilution in assay sample diluent and for those samples that were 211 
undetectable in the assay was repeated using undiluted samples. Secondly Matrix metalloproteinase 212 
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3 (MMP3) was selected to investigate the differential response to Stage I surgery (i.e. the proteome 213 
shift between Stages I and II) in non-responders to ACI. MMP3 was assessed using a human 214 
Quantikine
®
 ELISA (R&D Systems, Abingdon, UK). Samples were diluted 1 in 100 in assay kit diluent 215 
prior to assessment. Both ELISAs were carried out according to the manufacturer’s instructions and 216 
protein concentrations were normalised to the sample dilution factor. Statistical analysis was 217 
performed in GraphPad Prism version 6.0. Student’s t-tests were used to assess differential 218 
abundance. 219 
Assessment of the overlap of proteins identified from the two proteomic approaches  220 
In order to assess whether the use of two independent proteomic approaches allows for a greater 221 
number of significant protein changes to be identified, the datasets from this study (iTRAQ nLC-222 
MS/MS) and our previously published study assessing the same patient samples (LF LC-MS/MS; (3)) 223 
were compared to one another. Venn-diagrams were plotted using VENNY 2.1.0 software (37), to 224 
assess the overlap of differentially abundant proteins that was identified via the two approaches. 225 
Pathway and network analysis of proteomic datasets 226 
The datasets generated from both proteomic approaches were combined. Specifically, proteins which 227 
were differentially expressed (≥1.2 FC; p ≤0.05) in each biological comparison e.g. Stage I responders 228 
versus non-responders, in either proteomic approach were merged into a single dataset. A modest 229 
fold-change cut-off was used to ensure the greatest number of differentially abundant proteins could 230 
be included in the pathway and network analyses, as has been used previously (3,18). The iTRAQ 231 
nLC-MS/MS dataset independently and when merged with the LF dataset was analysed using 232 
pathway enrichment analysis (Ingenuity, Qiagen, US) to identify and visualise affected canonical 233 
pathways. Pathways with p≤0.005 were considered as statistically significant (Fisher’s exact test).  234 
The merged LF & iTRAQ nLC-MS/MS datasets of proteomic response to cartilage harvest (e.g. 235 
differential abundance between Stages I and II) in responders and non-responders were assessed 236 
using interactome network analysis, which is an unbiased mathematical method of visualising and 237 
interpreting complex interactions between large numbers of molecules (38). Interactome networks are 238 
made up of nodes (the individual objects being studied, e.g. proteins) and edges (the connections 239 
between the objects, e.g. known protein-protein interactions) (39). By studying groups of proteins that 240 
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are highly interconnected, known as modules, key functions within an interactome network can be 241 
highlighted (39). Conducting interactome network analysis alongside pathway enrichment analysis, 242 
allows for greater confidence in the selection of candidate pathways or molecules for further study as 243 
these represent two independent methods of mapping the data, known protein-protein interactions 244 
and text mining, respectively. The interactions between the differentially abundant proteins were 245 
assessed using the Protein Interaction Network Analysis For Multiple Sets (PINA4MS) app (40) in 246 
Cytoscape (v3.0) to generate network models based on protein-protein interactions. These models 247 
were either based upon only those proteins identified in the proteomic analyses (non-inferred nodes) 248 
or from proteins identified in the proteomic analyses alongside their inferred interactions (inferred 249 
nodes) (41). The Moduland (v2.8.3) algorithm (42) was applied to the interactome networks in 250 
Cytoscape (v3.0) to identify highly connected clusters of proteins (modules) that demarcate the 251 
hierarchical structure of the interactome network. The biological function of each module was 252 
assessed by analysing the proteins identified within each module using the pathway analysis tool in 253 
Reactome software (43,44). The significance of the pathway functions identified in Reactome was 254 
determined by Fisher’s exact test and p≤0.05 was considered statistically significant. 255 
 256 
 257 
 258 
 259 
 260 
 261 
 262 
 263 
 264 
 265 
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Results 266 
Proteomic data has been deposited in the PRIDE ProteomeXchange and can be accessed using the 267 
identifier PXD008321. 268 
Identification of proteins to predict ACI outcome prior to Stage I or Stage II 269 
iTRAQ nLC-MS/MS highlighted 16 proteins (≥±2.0 FC; p ≤0.05)  which were differentially abundant 270 
between responders and non-responders to ACI at baseline (immediately prior to Stage I) (Table 2). 271 
Prior to Stage II of the ACI procedure, 12 proteins displayed differential abundance between 272 
responders and non-responders (Table 3).  273 
At both stages of treatment, SF analysed using iTRAQ nLC-MS/MS identified a greater number of 274 
differentially abundant proteins between individuals who did or did not respond well to ACI compared 275 
to SF which had undergone protein normalisation using ProteoMiner
TM
 beads and LF LC-MS/MS 276 
analysis (3). Further, the two proteomic techniques identified no common differentially abundant 277 
proteins. 278 
Differential abundance of proteins a Stage II compared to Stage I of ACI 279 
Proteomic profiling of the SF using iTRAQ nLC-MS/MS highlighted a considerable effect of the 280 
cartilage harvest procedure (Stage I) in both responders and non-responders, with 70 and 54 proteins 281 
being differentially abundant between Stages I and II, respectively. Thus strengthening the similar 282 
findings from the analysis of these samples using LF LC-MS/MS (3). 283 
Interestingly, the iTRAQ nLC-MS/MS and LF LC-MS/MS identified no common Stage I compared to 284 
Stage II protein differences in the clinical responders (70 differentially abundant proteins identified by 285 
iTRAQ nLC-MS/MS and 14 identified by LF LC-MS/MS; Table 4). This lack of overlap between the 286 
two proteomic techniques is highlighted in Figure 1. There were, however, six proteins (gelsolin, 287 
vitamin K-dependent protein S, C4b binding protein alpha chain, fibrinogen alpha chain, fibrinogen 288 
beta chain and fibrinogen gamma chain) that were identified by both proteomic techniques in the non-289 
responders, all of which showed commonality in the direction of protein shift, across the MS platforms, 290 
with iTRAQ nLC-MS/MS consistently resulting in greater differences in abundance than those 291 
identified from the LF LC-MS/MS data. A total of 54 protein abundance changes between Stages I 292 
and II in non-responders were identified using iTRAQ nLC-MS/MS and 55 protein differences were 293 
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Protein 
Fold Change 
Identified using: 
Description Accession 
LF LC-MS/MS 
iTRAQ nLC-
MS/MS 
Complement C1s subcomponent  P09871 -5.15 
 
+ 
Haptoglobin  P00738 -4.49 
 
+ 
Mesencephalic astrocyte-derived neurotrophic 
factor  
P55145 2.15 
 
+ 
Plasma protease C1 inhibitor  P05155 2.19 
 
+ 
Ig kappa chain V-II region MIL P01615 2.60 + 
 
Bifunctional glutamate/proline--tRNA ligase  P07814 2.61 
 
+ 
Pigment epithelium-derived factor P36955 3.13 
 
+ 
Apolipoprotein A-IV  P06727 3.19 
 
+ 
Apolipoprotein L1  O14791 3.19 
 
+ 
N-acetylglucosamine-6-sulfatase  P15586 3.25 
 
+ 
Retinol-binding protein 4  P02753 3.34 
 
+ 
Inter-alpha-trypsin inhibitor heavy chain H1  P19827 3.37 
 
+ 
Extracellular matrix protein 1  Q16610 3.77 
 
+ 
Lumican  P51884 3.80 
 
+ 
Histidine-rich glycoprotein  P04196 3.84 
 
+ 
Endoplasmin  P14625 4.37 
 
+ 
Serum paraoxonase/arylesterase 1  P27169 4.41 
 
+ 
 294 
Table 2: Fold change of proteins that are differentially abundant (≥±2.0 FC; p ≤0.05; protein identified 295 
by at least 2 unique peptides) in the synovial fluid of clinical non-responders compared to clinical 296 
responders to ACI immediately prior to Stage I. Positive numbers denote higher abundance in non-297 
responders compared to responders. Proteins were identified using either protein dynamic 298 
compression coupled with label free quantification liquid-chromatography tandem mass spectrometry 299 
(LF LC-MS/MS) or no protein dynamic compression with isobaric tags for absolute and relative 300 
quantitation (iTRAQ) LC-MS/MS.  301 
 302 
 303 
 304 
 305 
 306 
 307 
 308 
 309 
 310 
 311 
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Protein 
Fold Change 
Identified using: 
Description Accession 
LF LC-MS/MS 
iTRAQ nLC-
MS/MS 
40S ribosomal protein S14  P62263 -8.63 
 
+ 
Kinectin  Q86UP2 -6.20 
 
+ 
Apolipoprotein C-III  P02656 -2.78 
 
+ 
High mobility group protein B1  P09429 -2.56 
 
+ 
Kininogen-1 P01042 2.27 
 
+ 
26S protease regulatory subunit 7  P35998 2.34 + 
 
26S proteasome non-ATPase regulatory subunit 13  Q9UNM6 2.43 + 
 
Alpha-enolase  P06733 2.56 
 
+ 
Alpha-2-HS-glycoprotein  P02765 2.78 
 
+ 
Hemopexin  P02790 2.88 
 
+ 
Ferritin light chain  P02792 2.91 + 
 
Platelet factor 4  P02776 3.26 + 
 
Thrombospondin-1  P07996 3.40 + 
 
Nucleosome assembly protein 1-like 1  P55209 4.94 + 
 
Cofilin-1  P23528 7.08 + 
 
EH domain-containing protein 1  Q9H4M9 7.30 + 
 
Hemoglobin subunit delta  P02042 8.09 
 
+ 
Protein S100-A6  P06703 8.39  + 
T-complex protein 1 subunit eta  Q99832 8.43 +  
Hemoglobin subunit beta  P68871 32.81  + 
Hemoglobin subunit alpha  P69905 44.06  + 
 312 
Table 3: Fold change of proteins that are differentially abundant (≥±2.0 FC; p ≤0.05; protein identified 313 
by at least 2 unique peptides) in the synovial fluid of clinical non-responders compared to clinical 314 
responders to ACI immediately prior to Stage II. Positive numbers denote higher abundance in non-315 
responders compared to responders. Proteins were identified using either protein dynamic 316 
compression coupled with label free quantification liquid-chromatography tandem mass spectrometry 317 
(LF LC-MS/MS) or no protein dynamic compression with isobaric tags for absolute and relative 318 
quantitation (iTRAQ) LC-MS/MS.  319 
 320 
 321 
 322 
 323 
 324 
 325 
 326 
 327 
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Protein Fold Change Identified using: 
Description Accession 
 
LF LC-MS/MS iTRAQ nLC-MS/MS 
Microtubule-associated protein 1B P46821 -20.65 +  
40S ribosomal protein S14  P62263 -16.75  + 
Protein disulfide-isomerase A6 Q15084 -7.59  + 
Nucleolin P19338 -5.11  + 
Histone H1.2  P16403 -3.84  + 
Stress-induced-phosphoprotein 1  P31948 -3.63  + 
Complement factor D  P00746 -3.44  + 
SH3 domain-binding glutamic acid-rich-like protein  O75368 -3.44  + 
Heterogeneous nuclear ribonucleoprotein U Q00839 -3.40  + 
78 kDa glucose-regulated protein  P11021 -3.25  + 
Cartilage oligomeric matrix protein  P49747 -3.10  + 
Annexin A2  P07335 -2.96  + 
Mesencephalic astrocyte-derived neurotrophic factor  P55145 -2.86  + 
Kinectin Q86UP2 -2.81  + 
Complement factor H-related protein 3  Q02985 -2.77 +  
Phosphatidylethanolamine-binding protein 1  P30086 -2.51  + 
Peroxiredoxin-4  Q13162 -2.49 +  
Regucalcin  Q15493 -2.44  + 
Malate dehydrogenase, mitochondrial  P40926 -2.44  + 
N-acetylglucosamine-6-sulfatase  P15586 -2.31  + 
Gelsolin  P06396 -2.27  + 
Alpha-endosulfine  O43768 -2.25  + 
Peptidyl-prolyl cis-trans isomerase FKBP3  Q00688 -2.11  + 
Hemopexin  P02790 2.05  + 
Serum paraoxonase/arylesterase 1  P27169 2.07  + 
Secreted phosphoprotein 24  Q13103 2.10 +  
Heparin cofactor 2  P05546 2.13  + 
Ferritin light chain  P02792 2.21 +  
Attractin  O75882 2.21  + 
Ig gamma-2 chain C region  P01859 2.23  + 
Plasma kallikrein  P03952 2.24  + 
Chondroitin sulfate proteoglycan 4  Q6UVK1 2.35 +  
Collagen alpha-2(I) chain  P08123 2.37 +  
Collagen alpha-1(V) chain  P20908 2.54 +  
CD5 antigen-like O43866 2.58  + 
Phospholipid transfer protein P55058 2.63  + 
Insulin-like growth factor-binding protein complex acid labile 
subunit  
P35858 2.68  + 
Prothrombin  P00734 2.68  + 
Beta-2-glycoprotein 1  P02749 2.78  + 
Collagen alpha-2(V) chain  P05997 2.84 + 
 
Plasma protease C1 inhibitor  P05155 2.91  + 
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Serum amyloid P-component  P02743 2.91  + 
Complement C1q subcomponent subunit B  P02746 3.01  + 
Collagen alpha-1(I) chain  P02452 3.05 +  
Alpha-2-antiplasmin P08697 3.10  + 
Alpha-1B-glycoprotein  P04217 3.19  + 
Complement factor B P00751 3.25  + 
Complement component C7  P10643 3.40  + 
Vitamin K-dependent protein S  P07225 3.42  + 
Apolipoprotein E  P02649 3.44  + 
Alpha-1-antichymotrypsin P01011 3.44  + 
Carboxypeptidase N subunit 2  P22792 3.53  + 
Vitronectin  P04004 3.63  + 
Inter-alpha-trypsin inhibitor heavy chain H3  Q06033 3.66  + 
Complement C5 O P01031 4.00  + 
Plasminogen  P00747 4.06  + 
Kininogen-1  P01042 4.17  + 
Platelet factor 4  P02776 4.26 +  
Inter-alpha-trypsin inhibitor heavy chain H2  P19823 4.49  + 
Periostin Q15063 4.57 +  
Apolipoprotein L1  O14791 4.61  + 
Protein 4.1  P11171 4.66 +  
26S proteasome non-ATPase regulatory subunit 13  Q9UNM6 4.78 +  
Inter-alpha-trypsin inhibitor heavy chain H1  P19827 5.01  + 
Inter-alpha-trypsin inhibitor heavy chain H4 Q14624 5.06  + 
Complement C1r subcomponent  P00736 5.15  + 
Complement component C6  P13671 5.45  + 
Complement factor H P08603 5.50  + 
Catalase  P04040 5.60  + 
Ficolin-3  O75636 6.43  + 
C4b-binding protein alpha chain P04003 7.05  + 
Ceruloplasmin P00450 7.51  + 
Pregnancy zone protein  P20742 8.09  + 
Fibrinogen alpha chain  P02671 8.40  + 
Apolipoprotein M O95445 9.04  + 
Protein S100-A6  P06703 9.82  + 
Hemoglobin subunit alpha  P69905 9.82  + 
Complement C1s subcomponent  P09871 10.00  + 
Ig mu chain C region  P01871 12.13  + 
Haptoglobin P00738 13.68  + 
Fibrinogen beta chain  P02675 16.90  + 
Hemoglobin subunit beta  P68871 19.41  + 
Fibrinogen gamma chain  P02679 23.55  + 
Table 4: Fold change of proteins that are differentially abundant (≥±2.0 FC; p ≤0.05; protein identified 328 
by at least 2 unique peptides) in the synovial fluid of clinical responders at Stage II compared to Stage 329 
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I of ACI. Positive numbers denote higher abundance at Stage II compared to Stage I. Proteins were 330 
identified using either protein dynamic compression coupled with label free quantification liquid-331 
chromatography tandem mass spectrometry (LF LC-MS/MS) or no protein dynamic compression with 332 
isobaric tags for absolute and relative quantitation (iTRAQ) LC-MS/MS.  333 
 334 
 335 
 336 
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 340 
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 352 
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identified by LF LC-MS/MS (Table 5; Figure 1). 357 
iTRAQ nLC-MS/MS confirmed that there is a significant response to the cartilage harvest 358 
procedure (Stage I) in non-responders to ACI 359 
Pathway analysis of the iTRAQ nLC-MS/MS identified proteins, using the pathway enrichment tools in 360 
Ingenuity, suggested that the proteins which were differentially abundant at Stage II compared to 361 
Stage I in non-responders are likely to impact on numerous canonical pathways; many of which were 362 
confirmatory of the previously published functional pathways identified from the LF nLC-MS/MS 363 
derived proteins (3). These functional pathways included acute phase response signalling (p=2.93 364 
x10
-1
), the complement system (p=2.11 x10
-1
) and Liver X receptor/ Retinoic X receptor (LXR/RXR) 365 
signalling (p=1.95 x10
-1
). Moreover, many more functional pathways were affected as a result of the 366 
proteins that were differentially abundant in response to Stage II compared to Stage I in non-367 
responders compared to responders (Supplementary Tables 1 and 2); reiterating that the SF 368 
proteome response to cartilage harvest is more distinct in non-responders to ACI.  369 
Similar pathways were identified from the differentially abundant proteins identified by the 370 
iTRAQ nLC-MS/MS and LF LC-MS/MS analyses  371 
Both iTRAQ nLC-MS/MS and LF LC-MS/MS analyses resulted in the acute phase response signalling 372 
being highlighted as one of the most significantly affected pathways in response to cartilage harvest in 373 
non-responders to ACI, therefore this pathway was further assessed. Figure 4 highlights that analysis 374 
of the SF proteome using the two independent proteomic techniques resulted in a greater number of 375 
differentially abundant downstream proteins being identified. In addition, many complementary 376 
proteins have been identified when comparing these datasets, with the vast majority of proteins that 377 
are predicted to be increased in the plasma (the standard bodily fluid referred to in Ingenuity) during 378 
the acute phase response being more abundant in the SF at Stage II compared to Stage I and vice 379 
versa. 380 
As the results of the two proteomic approaches seem to be complementary to one another, the two 381 
datasets were combined to generate a more comprehensive profile of the SF proteome. Pathway 382 
analysis using Ingenuity again identified many similar functional pathways as were identified via the 383 
independent LF LC-MS/MS and iTRAQ nLC-MS/MS datasets. The most significant canonical 384 
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Protein 
Fold Change 
Identified using: 
Description Accession 
LF LC-
MS/MS 
iTRAQ nLC-MS/MS 
Protein S100-A6  P06703 -4.49 
 
+ 
Annexin A1  P04083 -4.13 
 
+ 
Hemoglobin subunit beta  P68871 -4.09 
 
+ 
Complement factor D  P00746 -3.87 
 
+ 
Perilipin-4  Q96Q06 -3.87 + 
 
Gelsolin  P06396 -3.31 
 
+ 
Gelsolin P06396 -1.68 + 
 
Syntaxin-7  O15400 -3.31 + 
 
Fermitin family homolog 3  Q86UX7 -3.29 + 
 
Histone H1.2  P16403 -3.13 
 
+ 
Transaldolase  P37837 -3.08 
 
+ 
Neuroblast differentiation-associated protein AHNAK  Q09666 -2.78 + 
 
Heterogeneous nuclear ribonucleoprotein K P61978 -2.69 + 
 
Hyaluronan and proteoglycan link protein 3 Q96S86 -2.65 + 
 
Alpha-enolase  P06733 -2.63 
 
+ 
ATP-citrate synthase  P53396 -2.63 + 
 
Annexin A2  P07355 -2.56 
 
+ 
Fatty acid-binding protein, epidermal  Q01469 -2.43 + 
 
Peroxiredoxin-1 Q06830 -2.20 + 
 
Tripeptidyl-peptidase 1  O14773 -2.19 + 
 
Insulin-like growth factor-binding protein 6  P24592 -2.13 + 
 
Na(+)/H(+) exchange regulatory cofactor NHE-RF1  O14745 -2.11 + 
 
Peroxiredoxin-6  P30041 -2.08 + 
 
Histamine N-methyltransferase  P50135 -2.07 + 
 
Mortality factor 4-like protein 1 Q9UBU8 -2.06 + 
 
Transcription elongation factor A protein 1  P23193 -2.06 + 
 
Cartilage acidic protein 1  Q9NQ79 -2.03 
 
+ 
2',3'-cyclic-nucleotide 3'-phosphodiesterase  P09543 -1.20 + 
 
Fructose-bisphosphate aldolase A  P04075 -1.97 + 
 
Leucine zipper transcription factor-like protein 1  Q9NQ48 -1.94 + 
 
Protein S100-A13  Q99584 -1.94 + 
 
40S ribosomal protein S3  P23396 -1.93 + 
 
Filamin-A  P21333 -1.92 + 
 
Microtubule-associated protein RP/EB family member 1  Q15691 -1.92 + 
 
Nuclear migration protein nudC  Q9Y266 -1.90 + 
 
Prostaglandin E synthase 3  Q15185 -1.85 + 
 
Stress-induced-phosphoprotein 1 P31948 -1.85 + 
 
Cytokine-like protein 1 Q9NRR1 -1.81 + 
 
Plastin-2  P13796 -1.81 + 
 
Coronin-1C  Q9ULV4 -1.80 + 
 
Vinculin  P18206 -1.80 + 
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Cathepsin K  P43235 -1.79 + 
 
Hsc70-interacting protein P50502;Q8IZP2 -1.76 + 
 
Putative phospholipase B-like 2  Q8NHP8 -1.74 + 
 
Spectrin beta chain, erythrocytic  P11277 -1.73 + 
 
Complement factor I  P05156 2.11 
 
+ 
Alpha-1-antichymotrypsin P01011 2.22 
 
+ 
Titin Q8WZ42 2.23 
 
+ 
Cytoplasmic dynein 1 heavy chain 1  Q14204 2.23 + 
 
F-actin-capping protein subunit beta  P47756 2.25 + 
 
Mannan-binding lectin serine protease 1  P48740 2.26 + 
 
Serum amyloid P-component  P02743 2.27 
 
+ 
Complement component C6  P13671 2.29 
 
+ 
Thrombospondin-3  P49746 2.36 + 
 
Soluble scavenger receptor cysteine-rich domain-containing protein 
SSC5D  
A1L4H1 2.39 + 
 
Plasma kallikrein  P03952 2.42 
 
+ 
Complement factor B  P00751 2.47 
 
+ 
Afamin P43652 2.47 
 
+ 
Vitamin K-dependent protein S  P07225 2.49 + 
 
Vitamin K-dependent protein S  P07225 3.08 
 
+ 
Integrin beta-like protein 1  O95965 2.51 + 
 
C4b-binding protein beta chain P20851 2.55 + 
 
Fibronectin  P02751 2.58 + 
 
Clusterin P10909 2.65 
 
+ 
Vitronectin  P04004 2.68 
 
+ 
Bifunctional glutamate/proline--tRNA ligase  P07814 2.70 
 
+ 
Nucleobindin-1  Q02818 2.71 + 
 
Complement component C9  P02748 2.75 
 
+ 
Zinc-alpha-2-glycoprotein  P25311 2.75 
 
+ 
Complement C1r subcomponent  P00736 2.83 
 
+ 
Heparin cofactor 2  P05546 2.83 
 
+ 
Ferritin light chain  P02792 2.84 + 
 
Proteoglycan 4  Q92954 2.88 
 
+ 
C4b-binding protein alpha chain  P04003 2.91 + 
 
C4b-binding protein alpha chain  P04003 10.38 
 
+ 
Matrix Metalloproteinase 3  P08254 2.91 
 
+ 
Attractin  O75882 2.94 
 
+ 
Insulin-like growth factor-binding protein complex acid labile subunit  P35858 3.02 
 
+ 
Alpha-1B-glycoprotein  P04217 3.05 
 
+ 
Fibrinogen alpha chain  P02671 3.10 + 
 
Fibrinogen alpha chain P02671 11.91 
 
+ 
Lumican P51884 3.13 
 
+ 
Chondroitin sulfate proteoglycan 4  Q6UVK1 3.16 + 
 
Collagen alpha-2(V) chain  P05997 3.19 + 
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Complement C2  P06681 3.22 
 
+ 
Fibrinogen beta chain  P02675 3.25 + 
 
Fibrinogen beta chain P02675 18.37  + 
Secreted phosphoprotein 24  Q13103 3.26 + 
 
Matrix Metalloproteinase 1 P03956 3.33 + 
 
Latent-transforming growth factor beta-binding protein 1 Q14766 3.45 + 
 
Phospholipid transfer protein  P55058 3.47 
 
+ 
Inter-alpha-trypsin inhibitor heavy chain H3 Q06033 3.47 
 
+ 
Complement C1q tumor necrosis factor-related protein 3  Q9BXJ4 3.50 + 
 
Adipocyte enhancer-binding protein 1  Q8IUX7;Q8N436 3.51 + 
 
Adiponectin Q15848 3.52 + 
 
Fibrinogen gamma chain  P02679 3.79 + 
 
Fibrinogen gamma chain  P02679 18.37 
 
+ 
Plasminogen  P00747 3.84 
 
+ 
Apolipoprotein C-II  P02655 3.94 
 
+ 
CD5 antigen-like  O43866 4.17 
 
+ 
Collagen alpha-1(V) chain  P20908 4.26 + 
 
Complement factor H  P08603 4.57 
 
+ 
Inter-alpha-trypsin inhibitor heavy chain H4  Q14624 4.61 
 
+ 
Complement C5  P01031 4.74 
 
+ 
Collagen alpha-1(I) chain  P02452 4.84 + 
 
Ceruloplasmin  P00450 5.01 
 
+ 
Histidine-rich glycoprotein P04196 5.11 
 
+ 
Target of Nesh-SH3 Q7Z7G0 5.25 
 
+ 
Plasma protease C1 inhibitor  P05155 5.30 
 
+ 
Apolipoprotein M  O95445 5.65 
 
+ 
Inter-alpha-trypsin inhibitor heavy chain H2  P19823 5.70 
 
+ 
Periostin  Q15063 5.81 + 
 
Apolipoprotein C-III  P02656 5.92 
 
+ 
Kinectin Q86UP2 6.02 
 
+ 
Carboxypeptidase N subunit 2  P22792 7.73 
 
+ 
Serum paraoxonase/arylesterase 1 P27169 8.02 
 
+ 
Apolipoprotein L1  O14791 8.95 
 
+ 
Ig mu chain C region  P01871 13.30 
 
+ 
Apolipoprotein E  P02649 13.80 
 
+ 
Inter-alpha-trypsin inhibitor heavy chain H1  P19827 15.56 
 
+ 
Table 5: Fold change of proteins that are differentially abundant (≥±2.0 FC; p ≤0.05; protein identified 385 
by at least 2 unique peptides) in the synovial fluid of clinical non-responders at Stage II compared to 386 
Stage I. Positive numbers denote higher abundance at Stage II compared to Stage I of ACI. Proteins 387 
were identified using either protein dynamic compression coupled with label free quantification liquid-388 
chromatography tandem mass spectrometry (LF LC-MS/MS) or no protein dynamic compression with 389 
isobaric tags for absolute and relative quantitation (iTRAQ) LC-MS/MS. Proteins identified by both 390 
proteomic techniques are underlined and in italics. 391 
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pathways associated with the non-responder response to cartilage harvest (Stage II vs Stage I) were, 392 
acute phase response signalling (p=1.10 x10
-9
), intrinsic prothrombin activation pathway (p= 3.43X10
-393 
7
) and the complement system (p=1.22x10
-6
). Further, analysis of upstream regulators to these 394 
dysregulated proteins included those identified using the LF LC-MS/MS analysis data alone e.g. 395 
transforming growth factor beta 1 (TGFB1; p=2.05 x10
-13
), dihydrotestosterone (p= 4.48 x10
-11
) and 396 
peroxisome proliferator-activated receptor alpha (PPARA; p=1.09 x10
-9
) (3).  397 
The combined datasets were then used to generate unbiased interactome networks that represent the 398 
differentially abundant proteins (non-inferred networks), their likely interacting proteins (inferred 399 
networks) and how these proteins interact with one another, resulting in models of systemic protein 400 
response to cartilage harvest in either the responders or non-responders to ACI. Based on proteins 401 
that were differentially abundant between Stages I and II of ACI in non-responders, an interactome 402 
network consisting of 115 nodes (proteins) and 40 edges (protein-protein interactions) was generated. 403 
Further, an inferred network consisting of 2893 proteins and 35576 protein-protein interactions was 404 
generated based upon the addition of proteins that are likely to interact with the differentially abundant 405 
proteins (PINA4MS interactome database). Proteins that were differentially abundant in response to 406 
cartilage harvest in responders to ACI were used to generate interactome networks (non-inferred: 83 407 
nodes and 118 edges; inferred: 2084 nodes and 54007 edges). The ModuLand algorithm was applied 408 
to each of these networks to identify modules within the network that can be hierarchically ranked to 409 
identify groups of proteins that are the most fundamental in the functioning of the network. Figure 4 410 
highlights the top 10 modules from each of the networks generated. These modules again highlight 411 
the disparity between the ACI responder and non-responder response to cartilage harvest, with only 412 
modules centred on the proto-oncogene tyrosine-protein kinase (SRC) protein being identified in the 413 
inferred networks of both non-responder and responder groups. Interestingly, assessment of the 414 
functional pathways related to the ModuLand identified modules in the non-responder networks again 415 
highlighted regulation of the complement cascade (p= 1.68x10
-8
; Fisher’s Exact test), thus providing 416 
confidence in its importance based on identification via two independent bioinformatic approaches. 417 
 418 
 419 
 420 
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Discussion 421 
The recent NICE technology appraisal of ACI has recommended this treatment for a specific subset of 422 
patients with cartilage injury in the knee (2). The identification of novel biomarkers that can strengthen 423 
current patient demographic risk factors in predicting clinical outcomes (9), as well as developing a 424 
greater understanding of the underlying biology associated with success and failure will be beneficial, 425 
particularly as this treatment option is likely to be implemented on a wider scale in the near future. 426 
This study has built upon our previously published work (3,8), highlighting a number of novel protein 427 
candidates that have potential as biomarkers to predict ACI outcome. Moreover, comprehensive 428 
proteomic profiling of SF has further highlighted proteome differences between responders and non-429 
responders to ACI.  430 
In the majority of studies in which the SF proteome has been profiled, either high (11–16) or low (17–431 
22) abundance proteins have been assessed via depletion or non-depletion of abundant proteins prior 432 
to proteomic analysis. Our study highlights that the use of both a proteome dynamic range 433 
compression technique (Proteominer
TM
) (3) in tandem with analysis of non-depleted SF samples can 434 
provide a more holistic overview of proteome changes;, since both iTRAQ nLC-MS/MS and LF LC-435 
MS/MS highlighted large numbers of differentially abundant proteins between Stages I and II of ACI, 436 
with little crossover between techniques. This type of all-inclusive approach to unbiased whole-437 
proteome analysis of biological fluids may therefore be more successful in the identification of 438 
candidate biomarkers for other treatments/ disease states beyond those investigated here.  439 
A limitation of our previous study (3) was that very few proteins were identified as differentially 440 
abundant between responders and non-responders at baseline. In order for biomarkers aimed at 441 
predicting ACI success to be most useful clinically, patients who are likely to fail or respond to this 442 
procedure need to be identified prior to any surgical intervention. Interestingly, analysis of non-443 
dynamic range compressed proteins with iTRAQ nLC-MS/MS analysis was able to detect a greater 444 
number of differentially abundant proteins between responders and non-responders prior to Stage I 445 
surgery. The protein with most altered abundance in responders compared to non-responders at 446 
Stage I was C1s. This higher abundance in responders was confirmed in individual patient samples 447 
using a biochemical assay. C1s is a major constituent of the trimeric complement C1 protein, which 448 
triggers the classical complement pathway. Once activated, the classical complement pathway 449 
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promotes inflammation to enable the removal of damaged cells and/or microbes. Moreover, C1s has 450 
been shown to cleave insulin growth factor 1 (IGF-1) (45) and insulin like growth factor binding protein 451 
5 (IGFBP-5) (46). Both IGF-1 and IGFBP-5 are chondroprotective when in their intact state (45,47) 452 
and inhibition of C1s activity within the canine SF reduced cleavage of IGFBP-5 and IGF-1, resulting 453 
in reduced cartilage damage following anterior cruciate ligament rupture (45). These studies indicate 454 
that high C1s activity levels are likely detrimental to cartilage repair. In future studies, it would 455 
therefore be interesting to consider the activation state of C1s, alongside its overall abundance to 456 
determine how this protein might contribute to ACI success or failure. Further, the complement 457 
cascade is known to be important in the pathogenesis of OA, with OA patients demonstrating 458 
increased gene expression of complement agonists compared to inhibitors (48). OA related 459 
pathogenesis, such as the release of cartilage extracellular matrix molecules and the production of 460 
inflammatory mediators all induce complement activation (48). The increased pre-operative levels that 461 
we have identified in individuals who responded well to ACI, perhaps indicate that ACI has potential to 462 
be successful in individuals who may have developed an early OA phenotype. 463 
It must be noted that a limitation of the iTRAQ nLC-MS/MS analysis performed in this study is that 464 
pooled samples were analysed. Pooling of the samples may have resulted in some differentially 465 
abundant proteins not being detected, particularly if there was large variation between patients for 466 
some proteins. This again highlights the benefit of performing independent pooled and non-pooled 467 
proteomic techniques to optimise the number of differentially abundant proteins that can be identified. 468 
To perform an iTRAQ proteomics study, however, the number of samples that can be individually 469 
analysed by mass spectrometry is limited by the number of available isobaric tags; currently a 470 
maximum of 8 are commercially available. Therefore, it was decided that in order to assess 471 
differences across the experimental groups, replicates of human samples were best pooled to ensure 472 
protein differences represented the complexity of human variation. Further, C1s and MMP3 were 473 
validated in individual patient SFs by biochemical means, both of which demonstrated differential 474 
abundance in the same direction of change as identified using iTRAQ proteomics. The magnitude of 475 
differential abundance, however, was lower when assessed using ELISA compared to iTRAQ nLC-476 
MS/MS, thus highlighting the importance of biochemical validation of candidate biomarkers identified 477 
by iTRAQ nLC-MS/MS in individual technical replicate samples, particularly when considering small 478 
fold change differences from pooled samples. 479 
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Analysis of the iTRAQ nLC-MS/MS and LF LC-MS/MS datasets, both independently and when 480 
combined, has highlighted that there is a marked proteome shift in response to cartilage harvest, i.e. 481 
between Stages I and II of ACI. This analysis has resulted in a plethora of candidate biomarkers that 482 
may have the potential to inform as to whether an individual is likely to respond well to ACI prior to 483 
chondrocytes being implanted during Stage II. The proteoglycan, collagen II, IX and X degrading 484 
enzyme, MMP3 (49) has been biochemically validated as one of these candidate proteins that is 485 
significantly increased at Stage II compared to Stage I only in non-responders to ACI. If we can 486 
identify accurate Use of these biomarkers these willcould have the potential to prevent the burden of a 487 
second surgery in a patient for whom this therapy is likely to be unsuccessful, or could indicate that a 488 
greater period of time should be left from when the cartilage harvest procedure takes place and when 489 
the cells are implanted or that a tailored cartilage implantation procedure would be more efficacious. 490 
Alternatively, these candidate biomarkers could be used to determine whether a tailored cartilage 491 
implantation procedure would be more efficacious, for example alongside the use of anti-inflammatory 492 
drugs, molecule specific inhibitors or perhaps via the use of other cells such as mesenchymal stromal 493 
cells (MSCs) which have anti-inflammatory and immunomodulatory properties and have been shown 494 
to enhance the repair of cartilage defects (50,51). 495 
To investigate the significant proteome shift that exists in response to cartilage harvest, pathway 496 
analyses were performed to better distinguish the underlying biological mechanisms which dictate if 497 
an individual will respond to ACI or not. Interestingly, the number of biological pathways and functions 498 
that were differentially regulated at Stage II compared to Stage I was greater in the non-responders, 499 
again strengthening our previous findings that there is a marked and distinct proteome response to 500 
cartilage harvest in non-responders to ACI (3). The acute phase response was the pathway predicted 501 
to be most significantly differentially regulated in response to cartilage harvest in non-responders to 502 
ACI. In-depth assessment of individual protein changes within this pathway again highlighted the 503 
benefit of using independent proteomic techniques to profile the SF, as a large number of proteins 504 
were differentially abundant between Stages I and II, only three of which were identified using both 505 
techniques.  The acute phase response is the body’s first systemic response to immunological stress, 506 
trauma and surgery (52). At the site of injury/trauma, pro-inflammatory cytokines are normally 507 
released, activating inflammatory cells, ultimately resulting in inflammatory mediators and cytokines 508 
being released into the extracellular fluid compartment to be circulated within the blood (52). 509 
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Interestingly, previous bioinformatic analyses of the proteome of late OA compared to healthy 510 
controls, highlighted dysregulated acute phase response in the end-stage OA cohort (18). The 511 
exacerbated activation of the acute phase response in non-responders following initial surgery could 512 
indicate that these patients have a greater immune response to surgery and that they have a lesser 513 
ability to dampen down the acute phase following surgery or that they have already developed an 514 
advanced OA phenotype, deeming a therapy to repair cartilage injury unsuitable.  515 
Analysis of the canonical pathways which are associated with protein differences identified by either 516 
the iTRAQ nLC-MS/MS or the LF LC-MS/MS independently (1), highlighted many of the same 517 
biological pathways as being differentially regulated in response to cartilage harvest. Therefore, 518 
despite different proteins having been identified by the two methods, when these are considered 519 
alongside their likely interacting proteins in a ‘systemic’ manner, many common functional pathways 520 
have been identified irrespective of whole proteome coverage. Moreover, the overlap of biological 521 
pathways identified when comparing iTRAQ nLC-MS/MS and LF LC-MS/MS analyses adds 522 
confidence to our assertion that the biological mechanisms identified as underlying ACI success or 523 
failure warrant further investigation. 524 
Finally, the datasets of combined iTRAQ nLC-MS/MS and LF LC-MS/MS identified proteins were 525 
used to generate interactome models that represent the systemic proteome response to cartilage 526 
harvest that exists within the SF of both ACI responders and non-responders, from which biological 527 
functional pathways could be further studied. Biological functional pathways that were identified using 528 
this approach, as well as using IPA can most confidently be taken forward as candidates for further 529 
study, as they have been identified by independent bioinformatic methods. Furthermore, given the 530 
complexity of the knee joint environment, it is likely that the responder/non-responder phenotype is 531 
the result of many subtle protein changes which together contribute to overall dysfunction of a 532 
biological network, rather than the result of an individual biological molecule or pathway per se. 533 
Therefore, the interactome models generated in this study provide an important opportunity to 534 
consider how these proteins interact with one another and result in such phenotypes, as well as, 535 
providing a platform for further studies to investigate how potential modifications to the ACI procedure 536 
e.g. using co-incidental anti-inflammatory drugs in non-responders at Stage II, may alter these 537 
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biological networks. Thus, these models may provide a potential in silico tool for predicting ACI 538 
outcome, as is commonly used in drug development strategies (53).  539 
Conclusion 540 
This study has highlighted the advantage of using two independent proteomic techniques to profile a 541 
holistic overview of the SF proteome, ideal for unbiased identification of biomarker candidates. iTRAQ 542 
nLC-MS/MS analysis of SF samples from individuals who have either responded well or very poorly to 543 
ACI has highlighted proteins that with further validation have the potential to predict clinical outcome 544 
prior to treatment. We have confirmed that there is a marked SF proteome shift following cartilage 545 
injury, which is exacerbated in non-responders. Network and pathway analyses have demonstrated 546 
the complexity of the biological response underlying this proteome shift in non-responders, with 547 
several biological pathways identified that may act as targets for therapeutic intervention. 548 
 549 
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Figure 1: Venn-Diagrams representing the proteins identified using isobaric tags for relative and absolute 785 
quantitation (iTRAQ) proteomics and label-free quantitation (LF) proteomics which were differentially 786 
abundant (≥2.0 FC; p≤ 0.05) in the SF at Stage I (SI) compared to Stage II (SII) in responders (R) compared to 787 
non-responders (NR) to ACI.  788 
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 794 
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Figure 2: Biochemical validation of differentially abundant proteins identified using isobaric tagging for 798 
relative and absolute quantitation (iTRAQ) proteomics. (A) and (D) demonstrate the differential abundance of 799 
Complement C1S subcomponent and Matrix metalloproteinase-2, respectively as measured by iTRAQ mass-800 
spectrometry and by biochemical ELISA. Quantitative ELISA confirmed that (B) Complement C1S 801 
subcomponent is significantly decreased in the synovial fluid (SF) of non-responders (NR) compared to 802 
responders (R) to Autologous Chondrocyte Implantation (ACI) prior to cartilage harvest (Stage I; S1; p =0.04; 803 
Student’s t-test)(C) but was not significantly differentially abundant prior to chondrocyte implantation (Stage 804 
II; S2). (E) Matrix metalloproteinase-3 (MMP3) is not differentially abundant in response to cartilage harvest in 805 
ACI responders (F) but was biochemically confirmed to be differentially abundant in the SF of non-responders 806 
between Stages I and II of the ACI procedure (p =0.001; Student’s t-test). 807 
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 820 
Figure 3: Proteins of Acute Phase Signalling at Stage II compared to Stage I in non-responders to Autologous Chondrocyte Implantation (ACI).  821 
Several synovial fluid proteins that are downstream of acute phase response signalling were differentially abundant between Stages I and II of ACI.  Proteins 822 
edged in purple, orange and blue were identified using iTRAQ nLC-MS/MS, LF LC-MS/MS or by both techniques, respectively. (Adapted from Ingenuity).823 
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 824 
Figure 4: The ModuLand algorithm was applied to inferred and non-inferred interactome networks of 825 
differentially abundant proteins (±1.2FC; p≤0.05) between Stages I and II of ACI in clinical responders and 826 
non-responders. Modules were identified from both non-inferred (protein changes identified from proteomic 827 
analysis only) and inferred (identified protein changes and inferred proteins interactions) networks and are 828 
ranked based on their hierarchical network connectivity.829 
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